Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo

Abstract Modified Vaccinia virus Ankara (MVA) is a promising vaccine vector with an excellent safety profile. However, despite extensive pre-clinical and clinical testing, surprisingly little is known about the cellular tropism of MVA, especially in relevant animal species. Here, we performed in vit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Arwen F. Altenburg, Carolien E. van de Sandt, Bobby W. S. Li, Ronan J. MacLoughlin, Ron A. M. Fouchier, Geert van Amerongen, Asisa Volz, Rudi W. Hendriks, Rik L. de Swart, Gerd Sutter, Guus F. Rimmelzwaan, Rory D. de Vries
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ee315e57be3b4db7bdd91fe899f5fce5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ee315e57be3b4db7bdd91fe899f5fce5
record_format	dspace
spelling	oai:doaj.org-article:ee315e57be3b4db7bdd91fe899f5fce52021-12-02T16:07:01ZModified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo10.1038/s41598-017-08719-y2045-2322https://doaj.org/article/ee315e57be3b4db7bdd91fe899f5fce52017-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-08719-yhttps://doaj.org/toc/2045-2322Abstract Modified Vaccinia virus Ankara (MVA) is a promising vaccine vector with an excellent safety profile. However, despite extensive pre-clinical and clinical testing, surprisingly little is known about the cellular tropism of MVA, especially in relevant animal species. Here, we performed in vitro, ex vivo and in vivo experiments with recombinant MVA expressing green fluorescent protein (rMVA-GFP). In both human peripheral blood mononuclear cells and mouse lung explants, rMVA-GFP predominantly infected antigen presenting cells. Subsequent in vivo experiments performed in mice, ferrets and non-human primates indicated that preferential targeting of dendritic cells and alveolar macrophages was observed after respiratory administration, although subtle differences were observed between the respective animal species. Following intramuscular injection, rMVA-GFP was detected in interdigitating cells between myocytes, but also in myocytes themselves. These data are important in advancing our understanding of the basis for the immunogenicity of MVA-based vaccines and aid rational vaccine design and delivery strategies.Arwen F. AltenburgCarolien E. van de SandtBobby W. S. LiRonan J. MacLoughlinRon A. M. FouchierGeert van AmerongenAsisa VolzRudi W. HendriksRik L. de SwartGerd SutterGuus F. RimmelzwaanRory D. de VriesNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-14 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Arwen F. Altenburg Carolien E. van de Sandt Bobby W. S. Li Ronan J. MacLoughlin Ron A. M. Fouchier Geert van Amerongen Asisa Volz Rudi W. Hendriks Rik L. de Swart Gerd Sutter Guus F. Rimmelzwaan Rory D. de Vries Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo
description	Abstract Modified Vaccinia virus Ankara (MVA) is a promising vaccine vector with an excellent safety profile. However, despite extensive pre-clinical and clinical testing, surprisingly little is known about the cellular tropism of MVA, especially in relevant animal species. Here, we performed in vitro, ex vivo and in vivo experiments with recombinant MVA expressing green fluorescent protein (rMVA-GFP). In both human peripheral blood mononuclear cells and mouse lung explants, rMVA-GFP predominantly infected antigen presenting cells. Subsequent in vivo experiments performed in mice, ferrets and non-human primates indicated that preferential targeting of dendritic cells and alveolar macrophages was observed after respiratory administration, although subtle differences were observed between the respective animal species. Following intramuscular injection, rMVA-GFP was detected in interdigitating cells between myocytes, but also in myocytes themselves. These data are important in advancing our understanding of the basis for the immunogenicity of MVA-based vaccines and aid rational vaccine design and delivery strategies.
format	article
author	Arwen F. Altenburg Carolien E. van de Sandt Bobby W. S. Li Ronan J. MacLoughlin Ron A. M. Fouchier Geert van Amerongen Asisa Volz Rudi W. Hendriks Rik L. de Swart Gerd Sutter Guus F. Rimmelzwaan Rory D. de Vries
author_facet	Arwen F. Altenburg Carolien E. van de Sandt Bobby W. S. Li Ronan J. MacLoughlin Ron A. M. Fouchier Geert van Amerongen Asisa Volz Rudi W. Hendriks Rik L. de Swart Gerd Sutter Guus F. Rimmelzwaan Rory D. de Vries
author_sort	Arwen F. Altenburg
title	Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo
title_short	Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo
title_full	Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo
title_fullStr	Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo
title_full_unstemmed	Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo
title_sort	modified vaccinia virus ankara preferentially targets antigen presenting cells in vitro, ex vivo and in vivo
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/ee315e57be3b4db7bdd91fe899f5fce5
work_keys_str_mv	AT arwenfaltenburg modifiedvacciniavirusankarapreferentiallytargetsantigenpresentingcellsinvitroexvivoandinvivo AT carolienevandesandt modifiedvacciniavirusankarapreferentiallytargetsantigenpresentingcellsinvitroexvivoandinvivo AT bobbywsli modifiedvacciniavirusankarapreferentiallytargetsantigenpresentingcellsinvitroexvivoandinvivo AT ronanjmacloughlin modifiedvacciniavirusankarapreferentiallytargetsantigenpresentingcellsinvitroexvivoandinvivo AT ronamfouchier modifiedvacciniavirusankarapreferentiallytargetsantigenpresentingcellsinvitroexvivoandinvivo AT geertvanamerongen modifiedvacciniavirusankarapreferentiallytargetsantigenpresentingcellsinvitroexvivoandinvivo AT asisavolz modifiedvacciniavirusankarapreferentiallytargetsantigenpresentingcellsinvitroexvivoandinvivo AT rudiwhendriks modifiedvacciniavirusankarapreferentiallytargetsantigenpresentingcellsinvitroexvivoandinvivo AT rikldeswart modifiedvacciniavirusankarapreferentiallytargetsantigenpresentingcellsinvitroexvivoandinvivo AT gerdsutter modifiedvacciniavirusankarapreferentiallytargetsantigenpresentingcellsinvitroexvivoandinvivo AT guusfrimmelzwaan modifiedvacciniavirusankarapreferentiallytargetsantigenpresentingcellsinvitroexvivoandinvivo AT roryddevries modifiedvacciniavirusankarapreferentiallytargetsantigenpresentingcellsinvitroexvivoandinvivo
_version_	1718384814113947648

Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo

Ejemplares similares